Medical cannabis once epithelioid fibrous histiocytoma again, texas teeters on the edge of reform

Eduardo “eddie” lucio III, a democrat representing brownsville, introduced HB 1365. It expands legal medical cannabis beyond patients with intractable epilepsy epithelioid fibrous histiocytoma to those with a “debilitating medical condition,” including cancer, muscular dystrophy, crohn’s disease, and post-traumatic stress disorder. It explicitly allows patients to vape cannabis medicines but retains epithelioid fibrous histiocytoma the ban on smoking. It allows licensed medical-cannabis producers to operate up to four dispensaries rather than epithelioid fibrous histiocytoma just one. (companies can open more than four if the texas department epithelioid fibrous histiocytoma of safety “determines that additional locations are necessary.”) it also establishes a “cannabis therapeutic research review board” to approve studies on the plant’s medical value and “conduct periodic reviews of the research and participants.”

While an earlier version of HB 1365 eliminated “low-THC” language from the state’s current compassionate use act, the version that passed retained these restrictions. Also still in the bill: a controversial requirement that doctors “prescribe” and not “recommend” cannabis; cannabis is not an FDA-approved drug so doctors cannot “prescribe” it, among other legal reasons for the terminology.

While introducing the legislation, lucio told other legislators he was “very thankful” to bring a bill that could help “thousands of people in our state who are too sick epithelioid fibrous histiocytoma to function or live in constant, debilitating pain.” he said activists had played an integral role in bringing epithelioid fibrous histiocytoma the bill for a vote, in particular citing veterans and “passionate mothers” of sick children.

Two amendments passed after a short debate. The first, by mayes middleton, a republican out of wallisville, gives the legislature, rather than a state review board, final say over which illnesses could qualify someone for the epithelioid fibrous histiocytoma program. The second, by john zerwas, another republican, out of richmond, eases requirements on which doctors can offer a required second epithelioid fibrous histiocytoma opinion endorsing a patient for the program. Currently, only certified neurologists and epileptologists can refer patients. Zerwas’s amendment allows any texas doctor to fill that role.

Fort worth republican stephanie klick proposed the second bill, HB 3703. A registered nurse, klick introduced the original compassionate use act in 2015. Klick’s new bill expands medical-cannabis access to people with multiple sclerosis, spasticity, and all forms of epilepsy (not just intractable kinds). It authorizes “low-THC cannabis research” and allows licensed producers to “operate more than one dispensing location” if the texas DPS determines more than one location “necessary.” klick said it was a “great honor” to be working on cannabis issues again, describing her bill during testimony as a “truly medical program that follows the scientific data.”

Lucio’s bill now heads for the texas senate, which has sent mixed messages about whether it will consider epithelioid fibrous histiocytoma reforms to medical-cannabis access in texas. Klick’s bill will likely follow shortly. To stand a chance of passage before the next legislative epithelioid fibrous histiocytoma session in 2021, the bills will need to pass the senate before the epithelioid fibrous histiocytoma regular session ends on may 27.

Texas has been here before, teetering on the edge of reform. The state legislature only meets for around 140 days at epithelioid fibrous histiocytoma a time, and only on odd-numbered years. During the last session in 2017, two cannabis-reform bills seemed primed to pass—but they simply didn’t make it in time. “our clock has run out on us tonight on house epithelioid fibrous histiocytoma bill 2107,” state representative jason isaac, then a republican legislator from austin, said in a facebook live video from 2017, referring to a bill that would have also expanded the epithelioid fibrous histiocytoma state’s compassionate use program.